In vivo, interaction between the Fc portion of the agonist antibody and Fcγ receptors (FcγR) on immune cells is key to promoting tumor cell destruction [85,97,98,99]. In the clinical setting, on the other hand, expression of inhibitory FcγR or altered levels of FcγR due to ...